.has-img-background{ position: absolute; top: 20%; padding: 20px; } /* #img-desktop{ display: none; } #img-mobile{ display: block; } @media (min-width: 1024px){ #img-desktop{ display: block; } #img-mobile{ display: none; } }*/ @media (max-width: 426px){ .has-bg-img{ min-height: 250px !important; } .has-img-background{ position: absolute; top: 13%; padding: 20px; } } @media (max-width: 376px){ .banner-title{ font-size: 21px !important; } .banner-sub{ font-size: 18px !important; } .banner-caption{ font-size: 13px !important; } } @media (max-width: 451px){ .has-bg-img{ min-height: 400px !important; } .has-img-background{ top: 60%; } } Baby Genetic Screening Understand your baby's genes for a HEALTHIER FUTURE Cordlife Baby Genetic Screening Screens 0-3 years babies with more than 241 conditions caused by chromosomal abnormalities and disease-causing gene variants, providing you an expanded insight of your baby’s health condition. Quick and Effective Only a simple heel prick is required for testing. Clinically validated technology It uses high-density single nucleotide polymorphism (SNP) microarray platform for testing, which is the recommended first-tier genetic investigation for many conditions, including autism and intellectual disability. Internationally certified laboratory The sample will be tested by our CLIA-certified clinical lab partner based in South Korea. Managed by USFDA, CLIA sets stringent quality standards for labs performing tests on human specimens to ensure accurate, reliable and timely results. Currently, only CLIA-certified labs can report clinical genetic testing results to patients in the United States Detailed report insights A detailed interpretation of your baby’s test results will be provided within 6 to 8 weeks after the delivery of your baby. The report will include recommendations to help you make informed choices about your baby’s condition. The more you know about your baby, the better equipped you can be to address any potential health problems. Screening your newborn baby will facilitate early treatment and prevent long term detrimental effects to your baby’s health. Standard Baby Genetic Screening Comprehensive Baby Genetic Screening 241 types chromosomal abnormalities + 2 conditions: ADHD Atopic Dermatitis 241 types chromosomal abnormalities + 6 conditions: ADHD Atopic Dermatitis (Eczema) Asthma Allergic rhinitis Wilson disease Hearing loss Purchase Standard Baby Genetic Screening Purchase Comprehensive Baby Genetic Screening Frequently Asked Questions Since the hospital has already conducted tests on my baby, do I still need the Cordlife Baby Genetic Screening? Cordlife Baby Genetic Screening provides you an expanded coverage of conditions beyond the checks conducted at the hospital. With the access to more information of your baby’s health, you can take preemptive measures to manage the potential conditions that your child is predisposed to. This small step can help to make a difference in your child’s development and overall health. What should I do if the test result is positive? Genetic counseling service is available upon request. Our qualified genetic counselor will help you understand the result better and provide holistic advice on the follow-up options that you can take. Disclaimer and Test Limitation: Cordlife Baby Genetic Screening is tested by Eone-Diagnomics Genome Centre (EDGC), a CLIA-certified clinical lab based in South Korea with leading-edge technology for genome analysis. EDGC has a quality management system in place to ensure maximum accuracy of screening results. The test is only highly accurate for chromosomal abnormalities of aneuploidies, deletions and duplications (>200kb). As with any screening tests, false positive or false negative results cannot be completely eliminated due to various reasons including but not limited to specimen quality and other variables. This is a genetic screening test related to the genetic predisposition developmental disorders. It cannot be considered as a diagnostic test. Hence, the risk of a disorder should never be precluded solely on the basis of screening. If pathogenic variants are detected, follow up testing is recommended to confirm the results. Signs or symptoms observed should be followed up immediately by a professional healthcare provider. Reference: 1. Genetic profile and clinical application of chromosomal microarray in children with intellectual disability in Hong Kong. Hong Kong Med J. 2018;24:451-9.
